The medical and surgical treatment of tumoral seizures: Current and future perspectives

Renzo Guerrini, Anna Rosati, Flavio Giordano, Lorenzo Genitori, Carmen Barba

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Epilepsy surgery represents the main treatment option for epileptogenic brain tumors. Scalp video-electroencephalography (EEG) and magnetic resonance imaging (MRI) may suffice for defining lesional area and seizure-onset zone in discrete, surgically resectable lesions. The choice of timing for surgery requires a multidisciplinary evaluation, especially in children, when a "wait and see" approach is chosen. Discordant electroclinical and neuroimaging data and an ill-defined epileptogenic lesion require invasive investigations. A multimodal integrated approach may maximize the extent of resection while preserving cerebral function in the eloquent cortex. Radical removal of the tumor is the most important predictor of seizure freedom. Additional predictors include histopathology, age at surgery, duration of epilepsy, and seizure type. Patients with brain tumors are highly vulnerable in relation to the frequent drug-resistance of seizures, the potential interactions between antiepileptic drugs (AEDs) and chemotherapeutic agents (CMTs), and the risk of AED-related cognitive adverse events (24% higher than in the rest of the epilepsy population), in addition to brain damage resulting from tumor itself, surgery, and radiotherapy. No robust, randomized, controlled evidence supports the choice of AEDs for the treatment of seizures in patients with brain tumors. Newer AEDs have limited or no enzyme-inducing profile, prevalent renal excretion, lower plasma protein binding and, consequently, fewer interactions with CMTs. Enzymeinducing AEDs can lower serum levels of concomitantly administered CMTs. Class I evidence suggests that in patients with brain tumors who do not have a history of seizures, prophylactic use of AEDs is neutral or ineffective.

Original languageEnglish
Pages (from-to)84-90
Number of pages7
JournalEpilepsia
Volume54
Issue numberSUPPL. 9
DOIs
Publication statusPublished - 2013

Fingerprint

Anticonvulsants
Seizures
Brain Neoplasms
Epilepsy
Therapeutics
Scalp
Drug Resistance
Protein Binding
Neuroimaging
Blood Proteins
Electroencephalography
Neoplasms
Radiotherapy
Magnetic Resonance Imaging
Brain
Enzymes
Serum
Population

Keywords

  • Brain tumor
  • Medical treatment
  • Surgical treatment
  • Tumor-related epilepsy

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Medicine(all)

Cite this

The medical and surgical treatment of tumoral seizures : Current and future perspectives. / Guerrini, Renzo; Rosati, Anna; Giordano, Flavio; Genitori, Lorenzo; Barba, Carmen.

In: Epilepsia, Vol. 54, No. SUPPL. 9, 2013, p. 84-90.

Research output: Contribution to journalArticle

Guerrini, R, Rosati, A, Giordano, F, Genitori, L & Barba, C 2013, 'The medical and surgical treatment of tumoral seizures: Current and future perspectives', Epilepsia, vol. 54, no. SUPPL. 9, pp. 84-90. https://doi.org/10.1111/epi.12450
Guerrini, Renzo ; Rosati, Anna ; Giordano, Flavio ; Genitori, Lorenzo ; Barba, Carmen. / The medical and surgical treatment of tumoral seizures : Current and future perspectives. In: Epilepsia. 2013 ; Vol. 54, No. SUPPL. 9. pp. 84-90.
@article{0b3f0b4cca9445cf856d2a75b6b44d6f,
title = "The medical and surgical treatment of tumoral seizures: Current and future perspectives",
abstract = "Epilepsy surgery represents the main treatment option for epileptogenic brain tumors. Scalp video-electroencephalography (EEG) and magnetic resonance imaging (MRI) may suffice for defining lesional area and seizure-onset zone in discrete, surgically resectable lesions. The choice of timing for surgery requires a multidisciplinary evaluation, especially in children, when a {"}wait and see{"} approach is chosen. Discordant electroclinical and neuroimaging data and an ill-defined epileptogenic lesion require invasive investigations. A multimodal integrated approach may maximize the extent of resection while preserving cerebral function in the eloquent cortex. Radical removal of the tumor is the most important predictor of seizure freedom. Additional predictors include histopathology, age at surgery, duration of epilepsy, and seizure type. Patients with brain tumors are highly vulnerable in relation to the frequent drug-resistance of seizures, the potential interactions between antiepileptic drugs (AEDs) and chemotherapeutic agents (CMTs), and the risk of AED-related cognitive adverse events (24{\%} higher than in the rest of the epilepsy population), in addition to brain damage resulting from tumor itself, surgery, and radiotherapy. No robust, randomized, controlled evidence supports the choice of AEDs for the treatment of seizures in patients with brain tumors. Newer AEDs have limited or no enzyme-inducing profile, prevalent renal excretion, lower plasma protein binding and, consequently, fewer interactions with CMTs. Enzymeinducing AEDs can lower serum levels of concomitantly administered CMTs. Class I evidence suggests that in patients with brain tumors who do not have a history of seizures, prophylactic use of AEDs is neutral or ineffective.",
keywords = "Brain tumor, Medical treatment, Surgical treatment, Tumor-related epilepsy",
author = "Renzo Guerrini and Anna Rosati and Flavio Giordano and Lorenzo Genitori and Carmen Barba",
year = "2013",
doi = "10.1111/epi.12450",
language = "English",
volume = "54",
pages = "84--90",
journal = "Epilepsia",
issn = "0013-9580",
publisher = "Blackwell Publishing Inc.",
number = "SUPPL. 9",

}

TY - JOUR

T1 - The medical and surgical treatment of tumoral seizures

T2 - Current and future perspectives

AU - Guerrini, Renzo

AU - Rosati, Anna

AU - Giordano, Flavio

AU - Genitori, Lorenzo

AU - Barba, Carmen

PY - 2013

Y1 - 2013

N2 - Epilepsy surgery represents the main treatment option for epileptogenic brain tumors. Scalp video-electroencephalography (EEG) and magnetic resonance imaging (MRI) may suffice for defining lesional area and seizure-onset zone in discrete, surgically resectable lesions. The choice of timing for surgery requires a multidisciplinary evaluation, especially in children, when a "wait and see" approach is chosen. Discordant electroclinical and neuroimaging data and an ill-defined epileptogenic lesion require invasive investigations. A multimodal integrated approach may maximize the extent of resection while preserving cerebral function in the eloquent cortex. Radical removal of the tumor is the most important predictor of seizure freedom. Additional predictors include histopathology, age at surgery, duration of epilepsy, and seizure type. Patients with brain tumors are highly vulnerable in relation to the frequent drug-resistance of seizures, the potential interactions between antiepileptic drugs (AEDs) and chemotherapeutic agents (CMTs), and the risk of AED-related cognitive adverse events (24% higher than in the rest of the epilepsy population), in addition to brain damage resulting from tumor itself, surgery, and radiotherapy. No robust, randomized, controlled evidence supports the choice of AEDs for the treatment of seizures in patients with brain tumors. Newer AEDs have limited or no enzyme-inducing profile, prevalent renal excretion, lower plasma protein binding and, consequently, fewer interactions with CMTs. Enzymeinducing AEDs can lower serum levels of concomitantly administered CMTs. Class I evidence suggests that in patients with brain tumors who do not have a history of seizures, prophylactic use of AEDs is neutral or ineffective.

AB - Epilepsy surgery represents the main treatment option for epileptogenic brain tumors. Scalp video-electroencephalography (EEG) and magnetic resonance imaging (MRI) may suffice for defining lesional area and seizure-onset zone in discrete, surgically resectable lesions. The choice of timing for surgery requires a multidisciplinary evaluation, especially in children, when a "wait and see" approach is chosen. Discordant electroclinical and neuroimaging data and an ill-defined epileptogenic lesion require invasive investigations. A multimodal integrated approach may maximize the extent of resection while preserving cerebral function in the eloquent cortex. Radical removal of the tumor is the most important predictor of seizure freedom. Additional predictors include histopathology, age at surgery, duration of epilepsy, and seizure type. Patients with brain tumors are highly vulnerable in relation to the frequent drug-resistance of seizures, the potential interactions between antiepileptic drugs (AEDs) and chemotherapeutic agents (CMTs), and the risk of AED-related cognitive adverse events (24% higher than in the rest of the epilepsy population), in addition to brain damage resulting from tumor itself, surgery, and radiotherapy. No robust, randomized, controlled evidence supports the choice of AEDs for the treatment of seizures in patients with brain tumors. Newer AEDs have limited or no enzyme-inducing profile, prevalent renal excretion, lower plasma protein binding and, consequently, fewer interactions with CMTs. Enzymeinducing AEDs can lower serum levels of concomitantly administered CMTs. Class I evidence suggests that in patients with brain tumors who do not have a history of seizures, prophylactic use of AEDs is neutral or ineffective.

KW - Brain tumor

KW - Medical treatment

KW - Surgical treatment

KW - Tumor-related epilepsy

UR - http://www.scopus.com/inward/record.url?scp=84894323563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894323563&partnerID=8YFLogxK

U2 - 10.1111/epi.12450

DO - 10.1111/epi.12450

M3 - Article

C2 - 24328879

AN - SCOPUS:84894323563

VL - 54

SP - 84

EP - 90

JO - Epilepsia

JF - Epilepsia

SN - 0013-9580

IS - SUPPL. 9

ER -